Patents for A61P 35 - Antineoplastic agents (221,099)
04/2011
04/20/2011CN102018714A Formulations
04/20/2011CN102018698A Compounds and methods for treating estrogen receptor-related diseases
04/20/2011CN102018697A Kurarinone as effective component of drug having anti-angiogenic effect
04/20/2011CN102018693A Topical co-enzyme q10 formulations and methods of use
04/20/2011CN102018690A Anti-tumor medicament and application thereof
04/20/2011CN102018686A Mitomycin-containing film agent and preparation method thereof
04/20/2011CN102018672A Freeze-dried liposome composition of water-soluble medicament and preparation method thereof
04/20/2011CN102018670A Anticancer preparation and preparation method thereof
04/20/2011CN101664536B Traditional Chinese medicine composition for resisting tumors
04/20/2011CN101623437B Pulse-activating preparation for injection and preparation method thereof
04/20/2011CN101619312B Long non-coding RNA sequence of human melanoma cell specific expression and application thereof
04/20/2011CN101612406B siRNA aiming at RMP gene and application thereof
04/20/2011CN101580845B Vector capable of inducing cancer cell-apoptosis and use thereof
04/20/2011CN101575343B Norcantharidin esterified derivatives and preparation method thereof
04/20/2011CN101548947B Docetaxel nanometer lipid injection, preparation method and purpose thereof
04/20/2011CN101537184B Composition containing water-insoluble high-activity drug and preparation method thereof
04/20/2011CN101524341B Use of isoliquiritigenin in preparation of auxiliary therapeutic medicine for tumor radiation therapy
04/20/2011CN101502484B Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent
04/20/2011CN101480416B Cancer treating medical composition
04/20/2011CN101463058B Lanoline alkane type triterpenoid sexangulic acid, derivative thereof and preparation and use thereof
04/20/2011CN101444566B Application of saxifrage for preparing medicaments for treating benign tumor of thyroid
04/20/2011CN101429216B Organic stibium complex, preparation and uses thereof
04/20/2011CN101407743B Method for extracting and separating curcuma oil
04/20/2011CN101353678B Fermentation substrate of antineoplastic compound deacetylase fungal epoxy ethyl ester
04/20/2011CN101322723B Toad venom extract and preparation thereof
04/20/2011CN101307082B Galactose-artemisinin and method for preparing same
04/20/2011CN101277694B Novel crystal forms of irinotecan hydrochloride
04/20/2011CN101270157B Genetic engineering target glioma Acp-W1 resistant protein, preparation method and application
04/20/2011CN101264064B Vinpocetine freeze-dried powder for injection and preparation thereof
04/20/2011CN101255179B Novel amylaceum imine compound as well as preparation method and uses thereof
04/20/2011CN101239990B N-(2,3,4,5,6-pentahydroxyhexyl)-L-amino acid platinum ligand, preparation method and application thereof
04/20/2011CN101224306B Folic acid-polypeptide compound-mediated targeting anti-tumor prodrug and preparing method thereof
04/20/2011CN101205244B Bimetallic heptanuclear anticancer compounds as well as preparation and uses thereof
04/20/2011CN101199534B Anti-tumor function of raw panoxadiol derivative
04/20/2011CN101195609B Method for producing 5,6-dimethyl xanthenone-4-acetic acid, derivant and pharmaceutical formulation produced with the method
04/20/2011CN101185627B Nilotinib sustained-release implant for treating solid tumor
04/20/2011CN101176713B Carmustine sustained-release implantation agent for curing entity tumour
04/20/2011CN101139292B 4'-oxo carboxyl acid diphenyl ethylene alkyl derivative
04/20/2011CN101100487B Fusion protein capable of removing HPV E7 protein and its encoding gene and application
04/20/2011CN101053553B Biodegradable fluorourcacil polyester medicine-carried nanospheres and its preparation method
04/19/2011US7928255 Intermediates for the preparation of lipoxin A4 analogs
04/19/2011US7928239 Anticarcinogenic agents
04/19/2011US7928227 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders
04/19/2011US7928219 chemically modified nucleic acid molecule; cancer; carcinoma, neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases, restenosis and polycystic kidney disease
04/19/2011US7928218 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability
04/19/2011US7928213 Nucleic acids encoding chimeric CD154 polypeptides
04/19/2011US7928201 Serpentine transmembrane antigens expressed in human cancers and uses thereof
04/19/2011US7928130 Isoxazoline compounds having MIF antagonist activity
04/19/2011US7928125 N-aroyl cyclic amine derivatives as orexin receptor antagonists
04/19/2011US7928124 N-aroyl cyclic amine derivatives as orexin receptor antagonists
04/19/2011US7928097 Photoreactive compounds and compositions
04/19/2011US7928082 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
04/19/2011US7928073 Purified polypeptides having IL-13 receptor activity
04/19/2011US7928071 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
04/19/2011US7927835 Expression vector comprising nucleotide sequences coding bone morphogenic protein/selectin fusion for use in treatment and prvention of inflammatory diseases
04/19/2011US7927821 Methods of screening for compounds which bind G protein-coupled receptors
04/19/2011US7927806 Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
04/19/2011US7927803 Human MutY
04/19/2011US7927622 Methods of transnasal transport/immunization with highly adaptable carriers
04/19/2011CA2578047C Phenylaminopyridines
04/19/2011CA2553704C Substituted benzimidazoles and their use for inducing apoptosis
04/19/2011CA2516643C Method for preparing polymorphism of irinotecan hydrochloride
04/19/2011CA2476012C Substituted pyridinones as modulators of p38 map kinase
04/19/2011CA2464000C 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
04/19/2011CA2458452C Gnrh agonist combination drugs
04/19/2011CA2451680C Human dr4 antibodies and uses thereof
04/19/2011CA2441099C Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
04/19/2011CA2425271C Liposomes encapsulating anticancerous drugs and use thereof in the treatment of malignant tumours
04/19/2011CA2422094C Vaccination method
04/19/2011CA2421258C Truncated bard1 protein, and its diagnostic and therapeutic uses
04/19/2011CA2399187C Kahalalide compounds
04/19/2011CA2385659C Novel antiarrhythmic peptides
04/19/2011CA2362496C Polypeptide variants with increased heparin-binding ability
04/19/2011CA2295625C Imidazole derivatives as mdr modulators
04/14/2011WO2011044587A2 Cytoprotective or therapeutic plant composition
04/14/2011WO2011044545A2 Methods and compositions for targeted imaging
04/14/2011WO2011044533A2 Coating system and method for drug elution management
04/14/2011WO2011044504A1 Modulating levels of rna-binding proteins for the treatment of breast cancer
04/14/2011WO2011044481A1 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
04/14/2011WO2011044394A1 Purine derivatives useful as hsp90 inhibitors
04/14/2011WO2011044375A2 Apogossypolone derivatives as anticancer agents
04/14/2011WO2011044374A1 Capcna peptide therapeutics for cancer
04/14/2011WO2011044336A2 Human domain antibodies against components of the human insulin-like growth factor (igf) system
04/14/2011WO2011044327A1 Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
04/14/2011WO2011044072A1 Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
04/14/2011WO2011043980A1 Methods and compositions related to clot-binding lipid compounds
04/14/2011WO2011043809A2 Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
04/14/2011WO2011043564A2 Composition containing black ginseng extracts for preventing or treating liver cancer
04/14/2011WO2011043524A1 Anticancer composition containing human-derived adult stem cells
04/14/2011WO2011043502A1 Composite of photosensitizer-metal nanoparticles and composition for photodynamic therapy or diagnosis comprising same
04/14/2011WO2011043453A1 Activator for peroxisome proliferator activated receptor
04/14/2011WO2011043371A1 Oxazole compound
04/14/2011WO2011043369A1 Water-soluble porphyrin and process for production thereof
04/14/2011WO2011042798A1 Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
04/14/2011WO2011042797A1 Pyrazole derivatives as modulators of calcium release -activated calcium channel
04/14/2011WO2011042654A1 P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators
04/14/2011WO2011042534A1 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
04/14/2011WO2011042482A1 Polyphenols for use in the treatment of cancer
04/14/2011WO2011042477A1 Substituted pyrroles and imidazoles as estrogen receptor ligands
04/14/2011WO2011042475A1 Substituted pyrazoles as estrogen receptor ligands